MetaVia (NASDAQ:MTVA) Releases Earnings Results

MetaVia (NASDAQ:MTVA) issued its quarterly earnings data on Thursday. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03), Zacks reports.

MetaVia Stock Down 0.8%

NASDAQ:MTVA traded down $0.01 during trading hours on Thursday, reaching $1.19. The company had a trading volume of 64,112 shares, compared to its average volume of 148,932. The business’s 50-day simple moving average is $1.40 and its two-hundred day simple moving average is $4.58. The firm has a market cap of $6.14 million, a price-to-earnings ratio of -0.14 and a beta of 0.59. MetaVia has a twelve month low of $0.97 and a twelve month high of $19.03.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MTVA. Wall Street Zen upgraded MetaVia from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research note on Friday, April 24th. Finally, HC Wainwright reduced their price objective on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $26.50.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new stake in MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia at the end of the most recent quarter. Institutional investors and hedge funds own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.